Broad blockade antibody responses in human volunteers after immunization with a multivalent norovirus VLP candidate vaccine: immunological analyses from a phase I clinical trial - Wikidata - wikimedia - TriplyDB

Broad blockade antibody responses in human volunteers after immunization with a multivalent norovirus VLP candidate vaccine: immunological analyses from a phase I clinical trial

Broad blockade antibody responses in human volunteers after immunization with a multivalent norovirus VLP candidate vaccine: immunological analyses from a phase I clinical trial

http://www.wikidata.org/entity/Q35212408

about

Dengue Virus Envelope Dimer Epitope Monoclonal Antibodies Isolated from Dengue Patients Are Protective against Zika Virus Progress in Treatment of Viral Infections in Children with Acute Lymphoblastic Leukemia Mapping the Human Memory B Cell and Serum Neutralizing Antibody Responses to DENV4 Infection and Vaccination Transparency in reporting observational studies: reflections after a year Norovirus Regulation by Host and Microbe.Virus like particle-based vaccines against emerging infectious disease viruses.Antiviral targets of human noroviruses Early Detection of Epidemic GII-4 Norovirus Strains in UK and Malawi: Role of Surveillance of Sporadic Acute Gastroenteritis in Anticipating Global Epidemics Intranasal delivery of a bivalent norovirus vaccine formulated in an in situ gelling dry powder.Serum Immunoglobulin A Cross-Strain Blockade of Human Noroviruses Correlates of Protection against Norovirus Infection and Disease-Where Are We Now, Where Do We Go?Innate Resistance and Susceptibility to Norovirus Infection Frequent Use of the IgA Isotype in Human B Cells Encoding Potent Norovirus-Specific Monoclonal Antibodies That Block HBGA Binding.A new quaternary structure epitope on dengue virus serotype 2 is the target of durable type-specific neutralizing antibodies.Preclinical dose-ranging studies of a novel dry powder norovirus vaccine formulation Molecular evolution of the capsid gene in human norovirus genogroup II.Norovirus vaccines: Correlates of protection, challenges and limitations Structural basis for norovirus neutralization by an HBGA blocking human IgA antibody Impact of Pre-exposure History and Host Genetics on Antibody Avidity Following Norovirus Vaccination.Progress toward norovirus vaccines: considerations for further development and implementation in potential target populations.Recent advances in understanding norovirus pathogenesis.Seroprevalence in Household Raised Pigs Indicate High Exposure to GII Noroviruses in Rural Nicaragua.Prospects and Challenges in the Development of a Norovirus Vaccine.Genotype analysis of noroviruses associated with gastroenteritis outbreaks in childcare centres, Victoria, Australia, 2012-2015.Environmental Surveillance of Norovirus Genogroups I and II for Sensitive Detection of Epidemic Variants.Norovirus-Specific Memory T Cell Responses in Adult Human Donors.Effects of disinfectants against norovirus virus-like particles predict norovirus inactivation.Rapid Responses to 2 Virus-Like Particle Norovirus Vaccine Candidate Formulations in Healthy Adults: A Randomized Controlled Trial.Characterization of virus-like particles derived from a GII.3 norovirus strain distantly related with current dominating strains.Norovirus antagonism of B-cell antigen presentation results in impaired control of acute infection.The bulky and the sweet: How neutralizing antibodies and glycan receptors compete for virus binding.Emergence of Novel Human Norovirus GII.17 Strains Correlates with Changes in Blockade Antibody Epitopes.Characterization of a Norovirus-specific monoclonal antibody that exhibits wide spectrum binding activities.Antigenic characterization of a novel recombinant GII.P16-GII.4 Sydney norovirus strain with minor sequence variation leading to antibody escape.Norovirus Disease in Older Adults Living in Long-Term Care Facilities: Strategies for Management.Conformational Occlusion of Blockade Antibody Epitopes, a Novel Mechanism of GII.4 Human Norovirus Immune Evasion.Non-Human Primate Models of Enteric Viral Infections

P2860

Q26247258-5FA6EDDF-7E99-48A1-B51B-2BA9E3CA38FA Q26740588-1E682713-80EF-4A9E-8029-E73D4EC367C6 Q28114614-2D29EA59-55D4-487F-8AF3-30C610BF8D01 Q28608365-20745BE8-447D-4897-9099-BF6C3DD94AC6 Q30240631-983A348A-821C-427F-8FB0-5DE7E4CC0CC0 Q30249025-FDA421FC-1559-4D39-A4BE-D9AEE8150971 Q30249527-490D2C5C-F0F8-4303-8552-1D12DBC00BA3 Q30387327-69866352-102F-403C-979A-3DEE608F8D44 Q33703664-BF1EFCD3-60A2-42E6-982F-B3B5A40668C2 Q35837799-D3BC2CFA-E149-47F7-8A19-F615C089933F Q35999334-DC97788E-7FF8-45D8-9D0D-7080B4659DBC Q35999366-A0605C01-C443-46EA-A80C-D6B1747312E2 Q36063949-CA276CE2-B2AA-4341-941C-43FD463FC2E2 Q36205859-5189CBF9-A1FA-41D6-8610-84AA3A293A6D Q36642590-E5F93118-2419-4383-BA27-3F39E98FAFA3 Q37073042-845576BE-9101-4509-9115-71D1F90AA09D Q37135476-E1B99B3C-7AE1-421F-8D36-DADC56CC1F63 Q37323139-F90C19FB-C5DC-47AC-BC20-3A213665C39C Q38374766-FDCD3FFF-E109-4609-AE6A-C56A1A71739A Q38557262-5C3820E9-350D-4848-85AB-6AFCCE5B65A8 Q38816488-26C424BE-813A-489C-AF7B-2C50C5D57274 Q39770349-8D0C583A-CFF2-4DB0-89EF-9F1E09566F23 Q40102851-3F886B04-E676-4442-82EF-E2FAC895DD35 Q40248620-FAC82C5F-D1E0-47A3-A3FD-FA15B570D4DF Q40327653-EB67C190-6A85-43C9-82CA-902CF38E2EC4 Q40502202-EC84ECC6-8805-49E1-ABC4-AE7E3A36A084 Q40565387-36F09865-21E0-46E3-ADD4-5320E687B767 Q40632645-A7963A74-0684-4774-8A37-A07C8E7748D9 Q40731773-1EBF0519-9BA4-43C9-8DBD-EB534B4A2024 Q40743794-AE15CBBF-D4BB-4AF5-ADA9-5C535CFC397B Q41922286-34E260DD-EDEA-44C8-982C-BF2720CE80A3 Q41925431-C7AF39F6-08B1-40D8-8340-0D6CFF4FA447 Q47298344-025516B2-BB19-41EF-86D2-A5A02DF26A5C Q47560237-013F0020-DD7E-4B38-8BBA-1F8FB32B708E Q47569652-CE937E24-BCA4-4014-929E-652149FBD307 Q49401911-9AE6C772-4980-40C2-A61C-F35695F65AA0 Q57297793-9C520146-26B3-495F-8F9F-7285CAB11CD3

P2860

Broad blockade antibody responses in human volunteers after immunization with a multivalent norovirus VLP candidate vaccine: immunological analyses from a phase I clinical trial

http://www.wikidata.org/entity/Q35212408

description

2015 nî lūn-bûn

@nan

2015 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի մարտին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Broad blockade antibody respon ...... from a phase I clinical trial

@ast

Broad blockade antibody respon ...... from a phase I clinical trial

@en

type

label

Broad blockade antibody respon ...... from a phase I clinical trial

@ast

Broad blockade antibody respon ...... from a phase I clinical trial

@en

prefLabel

Broad blockade antibody respon ...... from a phase I clinical trial

@ast

Broad blockade antibody respon ...... from a phase I clinical trial

@en

P1433

Q35212408-D18B2A8D-E921-4E47-AE0D-F580B318C1C1

P1476

Q35212408-47A27D1F-27A2-4F0B-BE85-6CE1533F7A73

P2093

Q35212408-18B94A85-F813-4E64-A62A-BF0F60E88E4D

Q35212408-47AC770E-7975-4086-B2B2-D9ED0BCAC530

Q35212408-7F4FF2C9-309D-41A8-B999-F00DD6E9B5B5

Q35212408-8CAEF619-01C1-41E3-8E27-EAFD8ABD69C9

Q35212408-95BA96CE-51E5-4ABA-899B-91684699D2F4

Q35212408-B56A6D87-2EA4-4CAF-85E7-E9EA3FD82B0A

Q35212408-C2977388-4646-4BAD-8C41-BA6EBEF63D2E

Q35212408-C5281F50-6EF2-4DCC-96E0-90125D74A222

Q35212408-CFE15DE2-1763-43CF-A72D-7DE0BBFD107C

P2860

Q35212408-071A95F8-F907-44B0-AB07-8730472ED0AC

Q35212408-0948E1BC-6CA2-4A9F-8807-ED319C44BA71

Q35212408-0E4EF6B6-0394-44F3-8CAA-250D294DA26E

Q35212408-0F5A9F56-1A9F-4D58-B849-01750FD3313D

Q35212408-1502353A-9084-49D6-93A6-A35AD7E139E5

Q35212408-1580487E-C900-4605-A0CD-5D465F4E77EB

Q35212408-15F63074-384F-45EC-A884-BC98DAA63293

Q35212408-16E4E4DB-D5A7-4C84-BEED-0316377661FA

Q35212408-1E150D24-C9C4-4D64-85C5-891475D93460

Q35212408-20E48211-1935-4D92-AD7B-95C8B382C6E1

P304

Q35212408-DE187825-4ABC-4D69-8CA7-4F9311ED70F7

P31

Q35212408-8B972168-458A-487F-9608-9F14990C7768

P356

Q35212408-1933BC6E-3DD3-4CAC-B13F-B963A90642A6

P407

Q35212408-A180A253-6629-49BF-8823-FE7F22B7B031

P433

Q35212408-BD0CEF7C-9C2A-4439-9A57-95030499D828

P478

Q35212408-17CC27EB-B76F-4F56-98C3-5655144E7660

P50

Q35212408-43EEB16D-71D4-424F-8F71-FD36FC7385A6

Q35212408-72C48F50-6D40-4613-BAA7-40E1F484398E

Q35212408-8678D214-1E4E-4EBE-AB7B-2915B82B3CC5

P577

Q35212408-EE31AD39-2D4C-41C5-9774-42215E2229C6

P5875

Q35212408-84B48371-447C-4707-9C02-635255A99A88

P698

Q35212408-2D808D0A-63A7-4CD3-AE7E-7AABF5369EA3

P921

Q35212408-2FD64568-FFBA-47A0-B119-0DC559B98D16

Q35212408-411814B8-53C2-49A3-802C-2CED942540A8

Q35212408-77D48C36-5D91-49ED-83BE-9D3163F1A50C

Q35212408-C2BAE414-EDA1-40B4-AEA6-8373E9ECDB96

P932

Q35212408-7002FA30-72CF-4EA6-A4EB-539983FE4A47

P356

JOURNAL.PMED.1001807

P1433

P1476

Broad blockade antibody respon ...... from a phase I clinical trial

@en

P2093

Charles Richardson

http://www.w3.org/2001/XMLSchema#string

Frank Baehner

http://www.w3.org/2001/XMLSchema#string

Jennifer Ferreira

http://www.w3.org/2001/XMLSchema#string

Jesica Swanstrom

http://www.w3.org/2001/XMLSchema#string

Lisa C Lindesmith

http://www.w3.org/2001/XMLSchema#string

Martin T Ferris

http://www.w3.org/2001/XMLSchema#string

Paul M Mendelman

http://www.w3.org/2001/XMLSchema#string

Robert F Bargatze

http://www.w3.org/2001/XMLSchema#string

Robert R Goodwin

http://www.w3.org/2001/XMLSchema#string

P2860

Rapid evolution of pandemic noroviruses of the GII.4 lineage

Norovirus immunity and the great escape

Norovirus gastroenteritis outbreak with a secretor-independent susceptibility pattern, Sweden

Cellular and humoral immunity following Snow Mountain virus challenge

Rapid cloning of high-affinity human monoclonal antibodies against influenza virus

Immunogenetic mechanisms driving norovirus GII.4 antigenic variation

X-ray crystallographic structure of the Norwalk virus capsid

Preconfiguration of the antigen-binding site during affinity maturation of a broadly neutralizing influenza virus antibody.

Somatic hypermutation maintains antibody thermodynamic stability during affinity maturation

Norovirus gastroenteritis in immunocompromised patients

P304

e1001807

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PMED.1001807

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P50

P577

2015-03-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

274088002

http://www.w3.org/2001/XMLSchema#string

P698

25803642

http://www.w3.org/2001/XMLSchema#string

P921

phase I clinical trial

P932

4371888

http://www.w3.org/2001/XMLSchema#string